EVM
HUMA icon

Eaton Vance Management’s Humacyte HUMA Stock Holding History

Eaton Vance Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$7K – 2219
2021
Q4 		$7K Buy
+1,000
New +$9.89K ﹤0.01% 2590

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

Eaton Vance Management's HUMA Position: Q1 2022 in Review

Eaton Vance Management sold out of Humacyte (HUMA) in Q1 2022, closing a stake of 1,000 shares — an estimated $7K sold.

Eaton Vance Management first reported a position in HUMA in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 70 funds tracked by Wall St. Rank hold HUMA as of Q1 2022.

  • Eaton Vance Management reported no remaining Humacyte position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 1,000 Humacyte shares in Q1 2022, an estimated $7K.
  • Eaton Vance Management first reported a position in Humacyte in Q4 2021 and held it in 1 quarter.
  • Eaton Vance Management's Humacyte position peaked at $7K in Q4 2021.
  • 70 funds tracked by Wall St. Rank held Humacyte as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.